This HTML5 document contains 95 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/chemspider/
n12http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/mixture/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/wikipedia/
n14http://bio2rdf.org/drugbank:
n31http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/kegg-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/bindingdb/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n32http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/kegg-drug/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/pubchem-substance/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/iuphar/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n33http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/guide-to-pharmacology/
n20http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00784/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00784
rdf:type
n3:Drug
n3:description
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. [PubChem]
n3:dosage
n15:271B614C-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2 hours
n3:indication
For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.
n3:manufacturer
n8:271B6147-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00784 n21:DB00784
dcterms:title
Mefenamic acid
adms:identifier
n5:2593 n6:DB00784 n9:50134036 n10:3904 n19:Mefenamic_acid n26:4044 n28:46505405 n29:0677-1934-01 n30:PA450347 n31:C02168 n32:D00151 n33:2593
n3:mechanismOfAction
Mefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. As these receptors have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity, the symptoms of pain are temporarily reduced.
n3:packager
n8:271B6144-363D-11E5-9242-09173F13E4C5 n8:271B6145-363D-11E5-9242-09173F13E4C5 n8:271B6142-363D-11E5-9242-09173F13E4C5 n8:271B6143-363D-11E5-9242-09173F13E4C5 n8:271B6146-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The fecal route of elimination accounts for up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.3 The elimination half-life of mefenamic acid is approximately two hours. Mefenamic acid, its metabolites and conjugates are primarily excreted by the kidneys. Both renal and hepatic excretion are significant pathways of elimination.
n3:synonym
INF 3355 Ponstel N-2,3-Xylylanthranilic acid INF-3355 N-(2,3-Xylyl)-2-aminobenzoic acid CN-35355 Mefenaminsaeure CN 35355 Mefenaminsäure Acide méfénamique Acido mefenamico Acidum mefenamicum CI-473
n3:toxicity
Oral, rat LD<sub>50</sub>: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness.
n3:volumeOfDistribution
* 1.06 L/kg [Normal Healthy Adults (18-45 yr)]
n17:hasAHFSCode
n18:28-08-04-92
n3:foodInteraction
Take with food. Avoid alcohol.
n3:mixture
n23:271B6140-363D-11E5-9242-09173F13E4C5 n23:271B6141-363D-11E5-9242-09173F13E4C5 n23:271B613F-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
90%
n24:hasConcept
n25:M0013283
foaf:page
n12:mefenamic.htm n20:mefenamic-acid.html
n3:IUPAC-Name
n7:271B6151-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B6157-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B6156-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B6153-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B6154-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B6155-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B6167-363D-11E5-9242-09173F13E4C5 n7:271B614F-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B6169-363D-11E5-9242-09173F13E4C5 n7:271B614D-363D-11E5-9242-09173F13E4C5 n7:271B6150-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B616A-363D-11E5-9242-09173F13E4C5 n7:271B614E-363D-11E5-9242-09173F13E4C5
n3:pKa
n7:271B616B-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n22:M01AG01
n3:H-Bond-Acceptor-Count
n7:271B615D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B615E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B6158-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B6159-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B615B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B615A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B615C-363D-11E5-9242-09173F13E4C5
n3:absorption
Mefenamic acid is rapidly absorbed after oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
61-68-7
n3:category
n3:clearance
* Oral cl=21.23 L/hr [Healthy adults (18-45 yrs)]
n3:containedIn
n16:271B6148-363D-11E5-9242-09173F13E4C5 n16:271B6149-363D-11E5-9242-09173F13E4C5 n16:271B614A-363D-11E5-9242-09173F13E4C5 n16:271B614B-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B6163-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B6165-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B6166-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B6168-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B6162-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B6161-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B6164-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B6152-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B615F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B6160-363D-11E5-9242-09173F13E4C5